Prothena Corporation plc (PRTA NASDAQ) stock market data APIs
$9.81
0.1(1%)
as of October 23, 2025
Try our APIs with
free plan!
Prothena Corporation plc Financial Data Overview
Price chart is built with
Anychart
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prev. Close
9.81
Open
9.9066
High
10.0437
Low
9.6772
52 wk Range
4.32-18.88
Market Cap
525 M
Shares Outstanding
53 830 K
Revenue
10 341 K
EPS
-1.73
Beta
-0.116
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Prothena Corporation plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Prothena Corporation plc data using free add-ons & libraries
Get Prothena Corporation plc Fundamental Data
Prothena Corporation plc Fundamental data includes:
- Net Revenue: 10 341 K
- EBITDA: -248 103 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-04
- EPS/Forecast: -1.79
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prothena Corporation plc News
New
Prothena Corporation plc (PRTA): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Und...
Bristol Myers Alzheimer's Drug Earns FDA Fast Track
This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to its experimental drug BMS-986446,...
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti...
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Shares of Prothena Corporation (PRTA) have plunged 40% year to date against the industry’s gain of 6.6% as pipeline setbacks continue to weigh on the stock. While the company is striving hard to ad...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
